Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays?
about
Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular functionPrevalence of overweight in children and adolescents with attention deficit hyperactivity disorder and autism spectrum disorders: a chart reviewPharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveatsAttention-deficit/hyperactivity disorder (ADHD) and obesity: a systematic review of the literatureTrajectories of growth and symptoms of attention-deficit/hyperactivity disorder in children: a longitudinal study.Methylphenidate in children with hyperactivity: review and cost-utility analysis.A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects.The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial.ADHD, stimulant treatment, and growth: a longitudinal study.Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children.Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges.European guidelines on managing adverse effects of medication for ADHD.New developments in psychopharmacology of attention deficit hyperactivity disorder.Tics and shorter stature: should we be looking for an association?ADHD and overweight in boys: cross-sectional study with birth weight as a controlled factor.Growth on stimulant medication; clarifying the confusion: a review.Safety, efficacy and extended duration of action of mixed amphetamine salts extended-release capsules for the treatment of ADHD.The effects of long-term medication on growth in children and adolescents with ADHD: an observational study of a large cohort of real-life patientsGuanfacine Extended Release: A New Pharmacological Treatment Option in Europe.Long-term outcomes of stimulant medication in attention-deficit hyperactivity disorder.Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.Efficacy and safety of atomoxetine in the treatment of children and adolescents with attention deficit hyperactivity disorderPsychopharmacology: concepts and opinions about the use of stimulant medications.The NK1R-/- mouse phenotype suggests that small body size, with a sex- and diet-dependent excess in body mass and fat, are physical biomarkers for a human endophenotype with vulnerability to attention deficit hyperactivity disorder.Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details.Attention-Deficit/Hyperactivity Disorder (ADHD) and Obesity: Update 2016.Comparison of Height and Weight of 5-6 Year-old Boys with Attention Deficit Hyperactivity Disorder (ADHD) and Non-ADHD.Attention deficit disorder, stimulant use, and childhood body mass index trajectory.Comorbidity between ADHD and obesity: exploring shared mechanisms and clinical implications.A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD).Attention Deficit Hyperactivity Disorder (ADHD): Selected review of causes, comorbidity and treatment.Attention-deficit/hyperactivity disorder, iron deficiency, and obesity: is there a link?Pharmacotherapy of conduct disorder: Challenges, options and future directions.Chondrocyte proliferation, viability and differentiation is declined following administration of methylphenidate utilized for the treatment of attention-deficit/hyperactivity disorder.Pharmacotherapy of ADHD in young children.Growth dysregulation and ADHD: an epidemiologic study of children in France.[Analysis of methylphenidate's efficacy using the abbreviated version Conners' questionnaire in attention deficit hyperactivity disorder].Height, weight, IGF-I, IGFBP-3 and thyroid functions in prepubertal children with attention deficit hyperactivity disorder: effect of methylphenidate treatment.Successful treatment with atomoxetine of an adolescent boy with attention deficit/hyperactivity disorder, extreme obesity, and reduced melanocortin 4 receptor function.New drugs for treatment of attention-deficit/hyperactivity disorder.
P2860
Q22252308-039CEF28-2443-4BCF-B407-220F26166908Q25257179-C50EBEAF-C123-486F-A7E6-5BAA5FEAF3D2Q28138163-B8D59EF5-3DB6-413F-8D6C-D28311D27682Q28284641-C71A8117-628B-402A-A606-1EB150F62AB0Q34045531-76AC8294-709E-48DB-9124-283D9B1133EBQ34086479-2304D4EA-2839-4C3D-BDD0-DCBBED956AF8Q34147604-55E1BA0C-454B-45DF-B0B4-C1D5E9870663Q34233624-4E8F10B3-BF9A-4020-B356-99B550E12270Q34263102-086CDE84-1D63-4E8A-965D-91630A049AB5Q34303865-60E62C27-29A1-4883-BEE1-95113BBC8720Q34362939-F25097A7-1F6F-4115-A1E6-C94AD2E06A43Q34448884-78F92492-29A7-4DF8-A6DE-22525A5EBB66Q34481761-6EDF490F-A9F4-4F01-990E-E0FB52815796Q34567086-4E012899-94EE-4166-A090-19D6071A5C6FQ34924401-9F29E4BA-8D40-433D-80F2-8E7FC619B61FQ35284563-61FDB82A-F8C9-4A83-8FD5-1E40D3D5A739Q36161293-21F702A7-2E1B-4C32-B7F5-28EDA276E3D0Q36220220-77778CC0-917D-48AA-900F-206344F4C600Q36446854-78BD5480-3525-484B-879D-36FE269141FCQ36453293-AEFF5AA9-E7AB-4822-81F5-C7FC0399602DQ36492886-E21EEB73-DBCE-41DE-8480-6115A2DFF9E9Q36751226-4AC44D1F-5498-4A6C-A44F-901CF73B5E77Q37189436-0CBED063-3914-495D-A2FC-AB0C72877B83Q37196973-A03040E9-D41E-41BE-A033-F9D0F1D550B4Q37198296-E37EC363-6CAD-4CE3-9601-DC8C19B75EB9Q37595088-7B58F671-B2CA-4959-A587-2005892DF551Q37612868-77517C40-50FD-43B6-A93E-677C4C25140AQ37664977-8490AE37-EC25-4C46-9FDF-2D32F7A3DC8AQ37791318-6A9FD040-0CF0-4929-B4C9-A617D9EEA101Q38164670-7983165F-5850-452A-BB73-EF875EA7DA13Q38221613-07C5B7EC-5756-45C0-9496-4E4E6CD031FFQ38241643-1826750E-ECC8-4659-B94B-D64F6A50C612Q38839950-C9BB08B0-2FE5-4680-8473-B085A2075A15Q39193665-55131F1C-3517-4F73-A73A-9DF71E30B755Q42408226-F1DFF0BF-503C-4A9E-91AF-211F968FE076Q44254917-7043A5D7-CCFB-45EB-B2D5-364353E46FC0Q44880035-753DD69F-0390-4038-8FDB-DC8C2FADB452Q46408333-A55F5AF4-A7E6-4A21-A323-F45E55A08001Q46545906-E7653088-CECA-407A-8D0D-5FFE4808DF0CQ46576630-99E16995-670E-477C-8433-AD3A885BCFD5
P2860
Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays?
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Growth deficits in ADHD childr ...... rder-associated growth delays?
@en
Growth deficits in ADHD childr ...... rder-associated growth delays?
@nl
type
label
Growth deficits in ADHD childr ...... rder-associated growth delays?
@en
Growth deficits in ADHD childr ...... rder-associated growth delays?
@nl
prefLabel
Growth deficits in ADHD childr ...... rder-associated growth delays?
@en
Growth deficits in ADHD childr ...... rder-associated growth delays?
@nl
P2093
P1476
Growth deficits in ADHD childr ...... rder-associated growth delays?
@en
P2093
Biederman J
O'Donnell D
Spencer TJ
P304
P356
10.1097/00004583-199611000-00014
P577
1996-11-01T00:00:00Z